The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy.

Furthermore, there were numerically more acute coronary syndromes in patients treated with dabigatran, but this did not reach statistical significance. 10 Edoxaban The Hokusai-VTE trail was a randomized, double-blind, noninferiority study comparing the effects of edoxaban 60 mg once daily (or 30 mg once daily in patients with a creatinine clearance 30-50 mL/min or a body weight <60 kg) with warfarin in patients with an acute VTE. 11 The principal efficacy outcome was the incidence of symptomatic, recurrent VTE, whereas the principal safety measure was the composite of major or clinically relevant nonmajor bleeding (clinically relevant hemorrhage).

also in 111,027 other papers